New Insights on Tocilizumab for Giant Cell Arteritis

Understanding Giant Cell Arteritis

A recent study focusing on tocilizumab suggests a promising new treatment avenue for giant cell arteritis (GCA). This form of vasculitis, which primarily affects the elderly, is the most prevalent type of blood vessel inflammation. While GCA generally does not affect life expectancy, it can lead to severe complications, including optic neuropathy and potential blindness. The standard treatment has been long-term glucocorticoids, like prednisone, which may carry significant adverse effects. Historically, research had not identified any effective glucocorticoid-sparing alternatives until now.

Tocilizumab: A Potential New Treatment

Tocilizumab is a biologic medication that targets interleukin-6 (IL-6), a cytokine linked with GCA activity. An article published in JAMA Neurology outlines a study that evaluated tocilizumab’s efficacy in treating GCA. This randomized controlled trial, conducted by Stone and colleagues, divided participants into four treatment groups: a 26-week prednisone taper with placebo, a 52-week prednisone taper with placebo, a 26-week prednisone taper plus 162 mg of subcutaneous tocilizumab administered biweekly, and a 26-week prednisone taper plus 162 mg of tocilizumab administered weekly.

Efficacy of Tocilizumab in the Study

The primary outcome of the study was the rate of sustained glucocorticoid-free remission at 52 weeks. Results indicated that a significantly higher number of patients in the tocilizumab groups achieved this outcome compared to those receiving placebo. While potential side effects from tocilizumab include infections, thrombocytopenia, neutropenia, hyperlipidemia, and transaminitis, the incidence of serious side effects was lower in the tocilizumab groups compared to placebo. The findings highlighted the advantages of using tocilizumab alongside glucocorticoid tapering to enhance the likelihood of maintaining glucocorticoid-free remission at 52 weeks. Consequently, the U.S. Food and Drug Administration approved tocilizumab for GCA treatment.

Remaining Questions and Considerations

Despite these encouraging results, several questions about tocilizumab therapy in GCA persist. The long-term efficacy and safety of tocilizumab remain uncertain, and determining the most suitable candidates for this therapy is also unclear. A notable safety concern arises from reports of lower gastrointestinal perforation in rheumatoid arthritis patients treated with tocilizumab. Although the study by Stone and colleagues did not report such complications, the long-term risks remain undetermined due to the limited duration of tocilizumab use.

Additionally, many GCA patients are maintained on low-dose glucocorticoid therapy, but the comparative effectiveness of tocilizumab against low-dose glucocorticoids was not assessed in this study.

Current Recommendations

Given the existing uncertainties, it is premature to recommend tocilizumab as a first-line therapy or as a standalone treatment for giant cell arteritis. The most suitable candidates for tocilizumab may include patients who experience adverse effects from glucocorticoids or those who suffer from GCA flares while unable to reduce their glucocorticoid dosage. Nevertheless, the promising results pave the way for future investigations into tocilizumab as a treatment option for giant cell arteritis.

Conclusion

The study opens new doors for understanding the role of tocilizumab in treating giant cell arteritis, highlighting the need for further research to establish its long-term safety and efficacy.

Written by Maggie Leung, PharmD
Reference: Tamaki, H., & Hajj-Ali, R. A. (2017). Tocilizumab for Giant Cell Arteritis—A New Giant Step in an Old Disease. JAMA Neurology. doi:10.1001/jamaneurol.2017.3811